Zydus receives Final Approval from the USFDA for Loperamide Hydrochloride Capsules USP, 2 mg

Zydus Lifesciences Limited (including its subsidiaries/affiliates, hereinafter referred to as "Zydus") has received final approval for Loperamide Hydrochloride Capsules USP, 2 mg (USRLD: Imodium® Capsules) from the United States Food and Drug Administration (USFDA).

Loperamide hydrochloride capsule is indicated for the control and symptomatic relief of acute nonspecific diarrhea and chronic diarrhea associated with inflammatory bowel disease. The drug will be manufactured at the group's formulation manufacturing facility at SEZ, Ahmedabad (India).

Loperamide Hydrochloride Capsules USP, 2 mg had annual sales of USD 34.7 mn in the United States (IQVIA MAT, January 2023).

The group now has 356 approvals and has so far filed over 440* ANDAs since the commencement of the filing process in FY 2003-04.

Shares of Zydus Lifesciences Limited was last trading in BSE at Rs. 484.40 as compared to the previous close of Rs. 482.30. The total number of shares traded during the day was 42818 in over 1868 trades.

The stock hit an intraday high of Rs. 488.00 and intraday low of 478.45. The net turnover during the day was Rs. 20674609.00.

(*as of 31st December 2022)

Source : Equity Bulls

Keywords

ZydusLifesciences INE010B01027 Pharmaceuticals FinalApproval LoperamideHydrochlorideCapsules USFDA